

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CONFIRMATORY ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Xanthus Pharmaceutical, Inc.	11/14/2010
RECEIVING PARTY DATA	
Name:	Antisoma Plc
Street Address:	Chiswick Park Building 5, 566 Chiswick High Road
City:	London
State/Country:	UNITED KINGDOM
Postal Code:	W4 5YF
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	5420137
CORRESPONDENCE DATA	
Fax Number:	(978)341-0136
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	9783410036
Email:	tet@hbsr.com
Correspondent Name:	Susan M. Abelleira
Address Line 1:	530 Virginia Road, P.O. Box 9133
Address Line 2:	Hamilton, Brook, Smith & Reynolds, P.C.
Address Line 4:	Concord, MASSACHUSETTS 01742-9133
ATTORNEY DOCKET NUMBER:	3287.0036-000
NAME OF SUBMITTER:	Tiffany Testagrossa
Total Attachments: 3 source=USPATNO5420137ConfirmatoryASG_XANTHUS_TO_ANTISOMA#page1.tif source=USPATNO5420137ConfirmatoryASG_XANTHUS_TO_ANTISOMA#page2.tif source=USPATNO5420137ConfirmatoryASG_XANTHUS_TO_ANTISOMA#page3.tif	

CH \$40.00 5420137

501480167

PATENT  
REEL: 026016 FRAME: 0053

### CONFIRMATORY ASSIGNMENT

WHEREAS, Xanthus Pharmaceutical, Inc., ("Xanthus"), at 300 Technology Square, Cambridge, MA 02139, U.S.A.; having rights to the inventions as described in the intellectual property listed in Schedule A; sold and transferred all right, title and interest in and to the inventions as described in the intellectual property listed in Schedule A to Antisoma Plc, ("Antisoma Plc"), at Chiswick Park Building 5, 566 Chiswick High Road, London W4 5YP, United Kingdom pursuant to the terms and conditions of an Asset Purchase Agreement (the Xanthus APA) dated September 17, 2008 and the Amendment to Asset Purchase Agreement dated February 5, 2009.

Now, therefore, for good and valuable consideration, the receipt of which was hereby acknowledged by said Asset Purchase Agreement, Xanthus does hereby confirm that it did sell, transfer and convey its entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said inventions as described in said intellectual property listed in Schedule A, together with the entire right, title and interest in and to said applications and such Letters Patents as may issue on said intellectual property to Antisoma Plc.

Now, therefore, for good and valuable consideration, the receipt of which was hereby acknowledged by said Asset Purchase Agreement, Antisoma Plc confirms that it acquired the entire right, title and interest in the the inventions as described in the intellectual property listed in Schedule A.

#### **Xanthus Pharmaceutical, Inc.**



Glyn Edwards  
Name  
Title: CEO  
Date: Nov 14<sup>th</sup> 2010  
Address: 20 Ashley Park, Maidenhead  
SL6 8EZ, UK

Witness Signature [Signature]

Print Witness Name MARTIN A. PUE

Witness Signature Barbara Bonner

Print Witness Name BARBARA BONNER

#### **Antisoma Plc**

Eric Dadd  
Name ERIC DADD  
Title: CFO  
Date: Nov 14<sup>th</sup> 2010  
Address: 33 Lawn Crescent, Richmond, TW9 3N3,  
UK.

Witness Signature Barbara Bonner

Print Witness Name BARBARA BONNER

Witness Signature [Signature]

Print Witness Name MARTIN A. PUE

Schedule A

**Xanthus Patents**

Docket No.	Country	App/Pub/Pat No.	Subject
<b>XANAFIDE</b>			
XLSIP-202	US	US6693198	Organic acid salts of amonafide
	EU	EP1499595	
	BEL	EP1499595	
	FRA	EP1499595	
	GER	60313156.5-08	
	UK	EP1499595	
	IRE	EP1499595	
	ITA	EP1499595	
	SP	EP1499595	
	SWITZ	EP1499595	
	INDIA	3192/DERLP/2004	
	AUS	2003221771	
	CAN	2482445 A1	
	JPN	2002-197809	
XLSIP-202-1	US	US6989390	CIP of XLSIP-202
		US2005239816	
XLSIP-203	US	US5420137	amonafide salts (HCl) and mono-methanesulfonate
XLSIP-204	US	US5183821	Method for treating cancer with amonafide
XLSIP-213	USA	US 11/799,318	Combination of amonafide and AraC for AML
XLSIP-222	USA	PCT/US2008/00321	Treatment of cancers over-expressing multidrug resistant proteins with Amonafide
<b>SYMADEX</b>			
XLSIP-210	USA	11/342,314	Use of imidazoacridinones (inc. Symadex) for treating autoimmune & demyelinating disease
XLSIP-210	PCT	PCT/US2006/002952 WO2006081431	Use of imidazoacridinones (inc. Symadex) for treating autoimmune & demyelinating disease
	Australia	2006209225	
	Canada	2596144	
	China	200680007419.3	
	Europe	2006719695	
	Japan	2007553267	
	Korea	KR20070110046	
XLSIP-212-1	USA	US 11/893,375 US2006199546	CIP of XLSIP-212 (ABD) Novel Imidazoacridinone Compounds (NCE#1) Treating Inflammatory and Demyelinating Diseases & Cancer

NYCDMS/1098900.6

XLSIP-214	PCT	PCT/US2007/012947- WO2007143096	Imidazoacridinones (inc. Symadex) for Treating specific subtypes of cancer
XLSIP-215	PCT	PCT/US2007/017230 WO2008016665	Use of imidazoacridinones for Treating FLT3- Mediated Disorders
XLSIP-216	PCT	PCT/US2007/017224 WO2008016661	Morpholino imidazoacridinones for Treating Inflammatory and Demyelinating Diseases and Cancers
XLSIP-217	PCT	PCT/US2007/017300 WO2008016700	N-Oxide imidazoacridinones for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers
XLSIP-221	PCT	PCT/US2007/017222 WO2008016660	Compounds for the treatment of leukemias
XLSIP-228	USA	PCT/US08/09263	Indazol-Imidazoacridinones compounds and their use for the treatment of Cancer, Autoimmune and FLT3 and CSF-1R mediated diseases

#### P2045

XLSIP-219	US	US6358491	somatostatin analogs
XLSIP-219	AU	702,873	
XLSIP-219	PE	4,033	
XLSIP-219	TW	I243178	
XLSIP-219	EP	EP1208116	
XLSIP-219	JP	2001-545265	
XLSIP-219	CA	2,383,936	
XLSIP-219	AR	P000104412	
XLSIP-219	PH	1-2000-02340	
XLSIP-219	TH	59,853	

#### PARAMETABOLICS

XLSIP-005	US	US6284219	Method for determining metabolic function in vivo
XLSIP-006	US	US6610270	Method for determining metabolic function in vivo
XLSIP-008	US	US6740305	Method for determining gastric emptying rates

#### PYRUVATE ESTERS

Co-owner Bath  
Israel

XLSIP-208	US	US6846842
-----------	----	-----------

NYCDMS/1098900.6